Cargando…

Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response

BACKGROUND: Triptans are the most commonly prescribed acute treatments for migraine; however, not all triptan users experience adequate response. Information on real-world resource use and costs associated with triptan insufficient response are limited. METHODS: A retrospective claims analysis using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcus, Steven C, Shewale, Anand R, Silberstein, Stephen D, Lipton, Richard B, Young, William B, Viswanathan, Hema N, Doshi, Jalpa A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273744/ https://www.ncbi.nlm.nih.gov/pubmed/32223301 http://dx.doi.org/10.1177/0333102420915167

Ejemplares similares

Acute treatment patterns in patients with migraine newly initiating a triptan
por: Lipton, Richard B, et al.
Publicado: (2020)

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data
por: Dodick, David W., et al.
Publicado: (2020)

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
por: Lipton, Richard B., et al.
Publicado: (2022)

Costs and Utilization of Triptan Users Who Receive Drug Prophylaxis for Migraine Versus Triptan Users Who Do Not Receive Drug Prophylaxis
por: Etemad, Lida R., et al.
Publicado: (2005)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review
por: Leroux, Elizabeth, et al.
Publicado: (2020)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study
por: Tauqeer, Fatima, et al.
Publicado: (2021)

Headaches related to triptans therapy in patients of migrainous vertigo
por: Prakash, Sanjay, et al.
Publicado: (2008)

Efficacy of frovatriptan as compared to other triptans in migraine with aura
por: Evers, Stefan, et al.
Publicado: (2015)

Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010)

Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010)

Network meta-analysis of migraine disorder treatment by NSAIDs and triptans
por: Xu, Haiyang, et al.
Publicado: (2016)

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
por: Dodick, David W., et al.
Publicado: (2020)

Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data
por: Hirata, Koichi, et al.
Publicado: (2020)

Consistency vs. switching triptan treatment and headache-related disability: Results of the American migraine prevalence & prevention study
por: Buse, DC, et al.
Publicado: (2013)

Up to date on the use of triptans for child and adolescent migraine: state of the art
por: Calderoni, Dario, et al.
Publicado: (2001)

Triptans in prevention of menstrual migraine: a systematic review with meta-analysis
por: Hu, Yong, et al.
Publicado: (2013)

Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular Risk
por: Alwhaibi, Monira, et al.
Publicado: (2016)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Health Care Resource Utilization Following Initiation of a Triptan: A Retrospective Claims Analysis
por: Messali, Andrew, et al.
Publicado: (2014)

Polymorphisms of the Proinflammatory Cytokine Genes Modulate the Response to NSAIDs but Not to Triptans in Migraine Attacks
por: Rubino, Elisa, et al.
Publicado: (2022)

Evaluation of the 6‐item Identify Chronic Migraine screener in a large medical group
por: Pavlovic, Jelena M., et al.
Publicado: (2021)

Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan
por: Diener, Hans-Christoph, et al.
Publicado: (2008)

Theoretical analysis of headache recurrence in patients administered triptans for migraine based on receptor occupancy
por: Tokuoka, Kentaro, et al.
Publicado: (2015)

Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
por: Bérard, Anick, et al.
Publicado: (2021)

Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms
por: Kogelman, Lisette J. A., et al.
Publicado: (2023)

A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication
por: Lombard, Louise, et al.
Publicado: (2020)

Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine‐Associated Nausea and Prior Triptan Use on Efficacy
por: Lipton, Richard B., et al.
Publicado: (2017)

All triptans are not the same
por: Rapoport, Alan M., et al.
Publicado: (2001)

Clinical experience with triptans
por: Zanchin, Giorgio, et al.
Publicado: (2001)

Different characteristics of triptans
por: Pini, Luigi A., et al.
Publicado: (2004)

Success and failure of triptans
por: Saxena, Pramod R., et al.
Publicado: (2001)

Selecting the preferred triptans
por: McCrory, Douglas C., et al.
Publicado: (2004)

Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine
por: Dowson, A. J., et al.
Publicado: (2005)

Hair analysis for detection of triptans occasionally used or overused by migraine patients—a pilot study
por: Ferrari, Anna, et al.
Publicado: (2016)

Managing migraine with over-the-counter provision of triptans: the perspectives and readiness of Western Australian community pharmacists
por: Booth, Shaid, et al.
Publicado: (2019)

Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis
por: Yang, Chun-Pai, et al.
Publicado: (2021)

Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study
por: Viana, Michele, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tk7n8vjplmusbufaa2njj7aqqk